Dr. Sreenija Yarlagadda | Brain Tumor Management | Best Researcher Award
Research Associate 3 at Miami Cancer Institute, Baptist Health South Florida, United States
Dr. Sreenija Yarlagadda, MD, is a dedicated radiation oncologist and clinical researcher with extensive expertise in neuro-oncology, stereotactic radiosurgery, and advanced radiotherapy techniques. Currently serving as Research Associate III at the Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, she actively contributes to translational and clinical research in cutting-edge cancer care. Her academic journey began with an MBBS from Siddhartha Medical College followed by an MD in Radiation Oncology from Amrita Institute of Medical Sciences. Dr. Yarlagadda has co-authored over 50 peer-reviewed articles indexed in PubMed and Google Scholar, with a notable h-index of 5 and 95+ citations. Her prolific contributions extend to conferences, book chapters, and expert commentary in prestigious journals. She has consistently demonstrated leadership in multidisciplinary collaboration and precision oncology, particularly in the domains of brain metastases, hepatocellular carcinoma, and technological innovations in radiotherapy. An active member of several international oncology societies, Dr. Yarlagadda’s mission is to bridge clinical care with innovative research. Her commitment is further exemplified through mentoring, service to scientific publications, and a strong portfolio in academic presentations and professional workshops, making her a distinguished and promising expert in the global oncology landscape.
Profile
Education
Dr. Sreenija Yarlagadda laid a strong academic foundation through a rigorous medical and postgraduate education. She earned her Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from Siddhartha Medical College under the NTR University of Health Sciences, Andhra Pradesh, India, completing the program between August 2012 and April 2017. Following her graduation, she undertook a compulsory rotating internship at Government General Hospital, Vijayawada from March 2017 to March 2018, where she received comprehensive clinical training. Her passion for oncology led her to pursue a Doctor of Medicine (MD) in Radiation Oncology at the Amrita Institute of Medical Sciences, Kerala, India, from May 2019 to May 2022. During her postgraduate tenure, she developed a strong foundation in radiobiology, cancer pathophysiology, and advanced radiation techniques. In parallel, Dr. Yarlagadda completed several specialized certified courses including Biomedical Research (ICMR), Medical Physics (National Cancer Grid), and clinical trial management from renowned institutions such as the University of Miami and FDA. These courses significantly enhanced her capabilities in protocol development, ethical research practices, and advanced imaging techniques. Her formal academic journey, enriched with continuous professional learning, forms the backbone of her clinical excellence and research endeavors in radiation oncology.
Professional Experience
Dr. Sreenija Yarlagadda’s professional career encompasses a blend of clinical practice and high-impact research. She began her journey as a medical intern at Government General Hospital, Vijayawada, where she gained broad exposure to core medical disciplines. Her residency in the Department of Radiation Oncology at Amrita Institute of Medical Sciences (2019–2022) was pivotal in honing her clinical acumen in cancer care, during which she gained hands-on experience in IMRT, IGRT, SBRT, and brachytherapy. In September 2022, she transitioned to an international research role as Clinical Research Associate at Miami Cancer Institute, Baptist Health South Florida. Here, she is actively involved in advanced clinical research focused on stereotactic radiosurgery, neuro-oncology, proton therapy, and MR-guided radiation therapy. She collaborates with multidisciplinary teams to conduct investigator-initiated trials, engage in data-driven studies, and co-develop machine learning models for predictive oncology. Her expertise also extends to clinical workflow improvement, dosimetric analyses, and patient-centered care. Dr. Yarlagadda’s career reflects her deep commitment to integrating technological advancements with compassionate treatment delivery. She continues to contribute meaningfully to the academic and clinical oncology communities through her ongoing research, peer review responsibilities, and participation in numerous international and national conferences.
Research Interests
Dr. Sreenija Yarlagadda’s research interests lie at the intersection of clinical innovation and evidence-based oncologic care. Her primary focus areas include neuro-oncology, brain metastases, and hepatocellular carcinoma, with special emphasis on stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). She is particularly interested in integrating advanced imaging, machine learning algorithms, and radiomics to personalize radiation therapy and improve local control and survival outcomes in patients with complex cancers. Dr. Yarlagadda’s ongoing work on neurocognitive outcomes post-radiation and connectome analysis reflects her interest in balancing efficacy with long-term quality of life. Another critical area of her research involves MR-guided adaptive radiotherapy (SMART) and proton therapy for challenging anatomical sites like the brain and retroperitoneum. Additionally, she is involved in multiple prospective clinical trials aimed at refining treatment strategies for oligometastatic disease and evaluating novel toxicity metrics. Her research endeavors often bridge disciplines such as radiology, oncology, bioinformatics, and data science, enabling the translation of bench-side findings into bedside applications. Through robust collaboration with leading academic and clinical institutions, Dr. Yarlagadda aims to shape the future of oncology with a focus on precision medicine, patient-centric outcomes, and global access to advanced cancer treatments.
Research Skills
Dr. Sreenija Yarlagadda possesses a comprehensive array of research skills that underscore her multidisciplinary approach to cancer investigation and clinical innovation. She is proficient in data management platforms such as REDCap, SPSS, and advanced Excel for quantitative analysis. Her expertise extends to study design, protocol development, ethical research conduct, and compliance, validated through her certifications from FDA, University of Miami, and CITI program. Dr. Yarlagadda is well-versed in radiation oncology techniques and imaging software, including Raystation, Eclipse, ARIA, MIM, Monaco, and Mosaiq, which she integrates into her clinical trials. She excels at scientific writing and peer-reviewed publication, with a strong portfolio in manuscript drafting, figure preparation, and responding to editorial queries. Additionally, she is a peer reviewer for several leading journals including Cureus, BMC Cancer, and Scientific Reports. Her strong interpersonal skills enhance her role in collaborative research environments, and her fluency in multiple languages enables broader patient engagement in multiethnic trials. With formal training in motion management techniques, including 4DCT and fiducial tracking, Dr. Yarlagadda brings precision to data collection in high-tech clinical settings. Her holistic skillset makes her a valuable asset to translational oncology research initiatives worldwide.
Awards and Honors
Dr. Sreenija Yarlagadda has been consistently recognized for her academic and professional excellence across global platforms. Her prolific track record in peer-reviewed publishing, frequent invitations to present at international conferences such as ASTRO, ESTRO, and PTCOG, and her role in multi-institutional research collaborations demonstrate a high level of distinction. Her selection as an ad-hoc reviewer for reputable journals like Radiotherapy & Oncology, Scientific Reports, and Cancer Medicine reflects her respected standing in the academic community. Additionally, Dr. Yarlagadda’s engagement with prestigious scientific bodies such as the American Society for Radiation Oncology (ASTRO), European Society for Radiotherapy and Oncology (ESTRO), and SIGMA XI – The Scientific Research Honor Society, highlights her international recognition. Her rapid career progression from junior resident to a leading research associate in a premier U.S. cancer institute further exemplifies her merit. Through national seminars, quizzes, and competitive conference selections, including oral proffered papers at ESTRO and PTCOG, she has established a reputation for thought leadership. Dr. Yarlagadda’s continuous pursuit of academic rigor and scientific contribution firmly positions her as an emerging leader in global radiation oncology.
Publications
Dr. Sreenija Yarlagadda has authored an impressive portfolio of over 50 publications, including peer-reviewed journal articles, book chapters, expert commentaries, and conference proceedings. Her research contributions span high-impact journals indexed in PubMed and Google Scholar, addressing diverse topics such as stereotactic radiosurgery, hepatocellular carcinoma, oropharyngeal cancer surveillance, and adaptive MR-guided radiotherapy. Notable works include her studies on portal vein thrombosis management using robotic radiosurgery, dose-escalated proton therapy for retroperitoneal sarcomas, and the prognostic use of TTMV-HPV DNA in head and neck cancer. She has co-authored book chapters on liver toxicity and head & neck radiotherapy, alongside thought-provoking expert opinions published in major oncology journals. Her scientific rigor is further evident in numerous poster and oral presentations at global oncology summits such as ASTRO, ESTRO, and PTCOG. Dr. Yarlagadda’s interdisciplinary collaborations have led to publications in fields ranging from radiomics and neurocognitive assessment to connectome-based outcome prediction. This expansive and diverse body of work positions her as a significant contributor to the evolving landscape of radiation oncology and translational cancer research, reinforcing her role in both clinical innovation and academic advancement.
Conclusion
Dr. Sreenija Yarlagadda exemplifies a dynamic blend of clinical expertise, academic dedication, and scientific innovation in the field of radiation oncology. Her journey from foundational training in India to impactful research in the United States highlights her adaptability, intellectual rigor, and global outlook. She has distinguished herself through prolific scholarly contributions, collaborative research, and a steadfast commitment to improving oncologic outcomes. Her advanced training in stereotactic therapies, MR-guided techniques, and data-driven treatment planning ensures that she remains at the forefront of precision cancer therapy. As a mentor, reviewer, and conference speaker, she actively contributes to the growth of the academic and clinical oncology communities. Fluent in multiple languages and attuned to multicultural healthcare settings, Dr. Yarlagadda bridges international boundaries in research and patient care. Her vision encompasses not just therapeutic innovation but also holistic, compassionate, and informed patient management. With an expanding global footprint, she is poised to become a leading voice in next-generation oncology, contributing to both science and society. Her career trajectory promises ongoing contributions to evidence-based practice, multidisciplinary education, and the advancement of patient-centric radiotherapeutic care.